Switch from PI-Based Regimen to EVG-COBI-TDF-FTC

STRATEGY-PI (Study 115)
Switch from PI-Based Regimen to EVG-COBI-TDF-FTC

STRATEGY-PI: Design

Study Design: STRATEGY-PI

- **Background**: Open-label, randomized study, Phase 3b trial comparing switch to elvitegravir-cobicistat-tenofovir DF-emtricitabine versus continuation of baseline regimen of ritonavir + PI + tenofovir DF-emtricitabine

- **Inclusion Criteria (n = 433)**
  - HIV RNA < 50 copies/mL on ART for ≥ 6 months
  - Baseline regimen of RTV + PI + TDF-FTC
  - No prior virologic failure
  - No resistance to TDF or FTC
  - CrCl ≥70 mL/min

- **Treatment Arms**
  - EVG-COBI-TDF-FTC (Switch group)
  - Remain on RTV + PI + TDF-FTC (No switch group)

*NOTE*: 3 participants from switch group, and 1 participant from no-switch group, were excluded from study after screening for protocol violations.

Switch from PI-Based Regimen to EVG-COBI-TDF-FTC

STRATEGY-PI: Result

Week 48: Virologic Response (Modified Intent-to-Treat Analysis)

Interpretation: “Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir might be a useful regimen simplification option for virologically suppressed adults with HIV taking a multitablet ritonavir-boosted protease inhibitor regimen.”

Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.